Abstract

BackgroundStudies using validated questionnaires have shown a high prevalence of depression and/or anxiety in patients (pts) with AS, and such comorbidity has been found to be associated with AS outcome...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
The predictability of ASDAS on drug survival in patients with ankylosing spondylitis on biologic therapy: data from the KOBIO registry.
Min Jung Kim ... Sun Kyung Lee
Therapeutic advances in musculoskeletal disease | VOL. 15
Min Jung Kim, et. al.Min Jung Kim ... Sun Kyung Lee
01 Jan 2023
SAT0397 Comparison of Long-Term Drug Survival Outcome with Etanercept Treatment and Adalimumab Treatment of Ankylosing Spondylitis
C Van Denderen ... J Ruwaard
Annals of the Rheumatic Diseases | VOL. 75
C Van Denderen, et. al.C Van Denderen ... J Ruwaard
01 Jun 2016
Cost-Effectiveness of Treatment Strategies with Biologics in Accordance with Treatment Guidelines for Ankylosing Spondylitis: A Patient-Level Model.
Jenny H Kang ... Dimittri Delevry
Journal of managed care & specialty pharmacy | VOL. 26
Jenny H Kang, et. al.Jenny H Kang ... Dimittri Delevry
01 Oct 2020
Effectiveness and Drug Survival of TNF Inhibitors in the Treatment of Ankylosing Spondylitis: A Prospective Cohort Study.
Arto V Heinonen ... Jaana T Joensuu
The Journal of rheumatology | VOL. 42
Arto V Heinonen, et. al.Arto V Heinonen ... Jaana T Joensuu
15 Oct 2015
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers